These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Contribution of genetic factors for melanoma susceptibility in sporadic US melanoma patients. Council ML; Gardner JM; Helms C; Liu Y; Cornelius LA; Bowcock AM Exp Dermatol; 2009 May; 18(5):485-7. PubMed ID: 19320745 [TBL] [Abstract][Full Text] [Related]
13. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. Demenais F; Mohamdi H; Chaudru V; Goldstein AM; Newton Bishop JA; Bishop DT; Kanetsky PA; Hayward NK; Gillanders E; Elder DE; Avril MF; Azizi E; van Belle P; Bergman W; Bianchi-Scarrà G; Bressac-de Paillerets B; Calista D; Carrera C; Hansson J; Harland M; Hogg D; Höiom V; Holland EA; Ingvar C; Landi MT; Lang JM; Mackie RM; Mann GJ; Ming ME; Njauw CJ; Olsson H; Palmer J; Pastorino L; Puig S; Randerson-Moor J; Stark M; Tsao H; Tucker MA; van der Velden P; Yang XR; Gruis N; J Natl Cancer Inst; 2010 Oct; 102(20):1568-83. PubMed ID: 20876876 [TBL] [Abstract][Full Text] [Related]
14. Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype. Nielsen K; Harbst K; Måsbäck A; Jönsson G; Borg A; Olsson H; Ingvar C Melanoma Res; 2010 Aug; 20(4):266-72. PubMed ID: 20526219 [TBL] [Abstract][Full Text] [Related]
15. CDKN2A as a uveal and cutaneous melanoma susceptibility gene. Kannengiesser C; Avril MF; Spatz A; Laud K; Lenoir GM; Bressac-de-Paillerets B Genes Chromosomes Cancer; 2003 Nov; 38(3):265-8. PubMed ID: 14506702 [TBL] [Abstract][Full Text] [Related]
16. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia. Ruiz A; Puig S; Malvehy J; Lázaro C; Lynch M; Gimenez-Arnau AM; Puig L; Sánchez-Conejo J; Estivill X; Castel T J Med Genet; 1999 Jun; 36(6):490-3. PubMed ID: 10874641 [TBL] [Abstract][Full Text] [Related]
17. High incidence of primary melanomas in an MC1R RHC homozygote/CDKN2A mutant genotype patient. Sinnya S; Jagirdar K; De'Ambrosis B; McMeniman E; Sturm RA; Soyer HP Arch Dermatol Res; 2015 Oct; 307(8):741-5. PubMed ID: 26103950 [TBL] [Abstract][Full Text] [Related]
18. Contribution of melanocortin-1 receptor gene variants to sporadic cutaneous melanoma risk in a population in central Italy: a case-control study. Fargnoli MC; Altobelli E; Keller G; Chimenti S; Höfler H; Peris K Melanoma Res; 2006 Apr; 16(2):175-82. PubMed ID: 16567973 [TBL] [Abstract][Full Text] [Related]
19. Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countries. Goldstein AM; Chaudru V; Ghiorzo P; Badenas C; Malvehy J; Pastorino L; Laud K; Hulley B; Avril MF; Puig-Butille JA; Miniere A; Marti R; Chompret A; Cuellar F; Kolm I; Mila M; Tucker MA; Demenais F; Bianchi-Scarra G; Puig S; de-Paillerets BB Int J Cancer; 2007 Aug; 121(4):825-31. PubMed ID: 17397031 [TBL] [Abstract][Full Text] [Related]
20. p53 codon 72 Pro homozygosity increases the risk of cutaneous melanoma in individuals with dark skin complexion and among noncarriers of melanocortin 1 receptor red hair variants. Stefanaki I; Stratigos AJ; Dimisianos G; Nikolaou V; Papadopoulos O; Polydorou D; Gogas H; Tsoutsos D; Panagiotou P; Kanavakis E; Antoniou C; Katsambas AD Br J Dermatol; 2007 Feb; 156(2):357-62. PubMed ID: 17223878 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]